What is a new drug worth? An innovative model for performance‐based pricing. (25th September 2014)

• Record Type: Journal Article
• Authors: Dranitsaris, G.; Dorward, K.; Owens, R.C.; Schipper, H.
• Is Part Of: European journal of cancer care. Volume 24:Number 3(2015:May)
• Page Start: 313
• Page End: 320
• Publication Date: 2014-09-25
• Subjects: Cancer -- Nursing -- Periodicals; 616.994
• DOI: 10.1111/ecc.12240
• Languages: English
• ISSNs: 0961-5423

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>This article focuses on a novel method to derive prices for new pharmaceuticals by making price a function of drug performance. We briefly review current models for determining price for a new product and discuss alternatives that have historically been favoured by various funding bodies. The progressive approach to drug pricing, proposed herein, may better address the views and concerns of multiple stakeholders in a developed healthcare system by acknowledging and incorporating input from disparate parties via comprehensive and successive negotiation stages. In proposing a valid construct for performance‐based pricing, the following model seeks to achieve several crucial objectives: earlier and wider access to new treatments; improved transparency in drug pricing; multi‐stakeholder involvement through phased pricing negotiations; recognition of innovative product performance and latent changes in value; an earlier and more predictable return for developers without sacrificing total return on investment (ROI); more involved and informed risk sharing by the end‐user.</p> </abstract>